SnET2 (tin ethyl etiopurpurin), a light-activated drug: Phase I and II Update

PDT Inc. (PDTI), Santa Barbara, Calif. Product: SnET2 (tin ethyl etiopurpurin), a light-activated drug Indication: Breast cancer and basal cell carcinoma Status: PDTI began Phase II/III trials with it...